https://orcid.org/0000-0002-1682-5547
References
- Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44–57.e9. doi:10.1016/j.chom.2020.11.007.
- Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann H-H, Michailidis E, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020;9. doi:10.7554/eLife.61312.
- Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nature Medicine. 2021;27:205–11. doi:10.1038/s41591-021-01230-y.
- Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29:477–88.e4. doi:10.1016/j.chom.2021.01.014.